Adial Pharmaceuticals

General Information

(Unit offering – warrants traded “ADILW.”)

We are a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD”) using our lead investigational new drug product, AD04, a selective serotonin-3 antagonist (i.e., a “5-HT3 antagonist”). The active ingredient in AD04 is ondansetron, which is also the active ingredient in Zofran®, an approved drug for treating nausea and emesis. AUD is characterized by an urge to consume alcohol and an inability to control the levels of consumption. We intend to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.

Employees: 3
Founded: 2010
Contact Information
Address 1180 Seminole Trail, Suite 495, Charlottesville, VA 22901, US
Phone Number (434) 422-9800
Web Address
View Prospectus: Adial Pharmaceuticals
Financial Information
Market Cap $32.5mil
Revenues $0 mil (last 12 months)
Net Income $-1.3 mil (last 12 months)
IPO Profile
Symbol ADIL
Exchange NASDAQ
Shares (millions): 1.5
Price range $5.00 - $5.00
Est. $ Volume $7.3 mil
Manager / Joint Managers Joseph Gunnar & Co.
CO-Managers Dawson James Securities
Expected To Trade: 7/27/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change